Global Therapeutic Monoclonal Antibodies Drug Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Therapeutic Monoclonal Antibodies Drug market size was valued at US$ 201980 million in 2024 and is forecast to a readjusted size of USD 409430 million by 2031 with a CAGR of 10.7% during review period.

Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.

The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.

This report is a detailed and comprehensive analysis for global Therapeutic Monoclonal Antibodies Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Therapeutic Monoclonal Antibodies Drug market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2020-2031

Global Therapeutic Monoclonal Antibodies Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2020-2031

Global Therapeutic Monoclonal Antibodies Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2020-2031

Global Therapeutic Monoclonal Antibodies Drug market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/Ton), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Therapeutic Monoclonal Antibodies Drug

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Therapeutic Monoclonal Antibodies Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Therapeutic Monoclonal Antibodies Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Mouse-derived Antibodies
Chimeric Antibodies
Humanized Antibodies

Market segment by Application
Immune Diseases
Cancer
Other

Major players covered
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
Regeneron
Innovent
Hengrui Medicine

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Therapeutic Monoclonal Antibodies Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Therapeutic Monoclonal Antibodies Drug, with price, sales quantity, revenue, and global market share of Therapeutic Monoclonal Antibodies Drug from 2020 to 2025.

Chapter 3, the Therapeutic Monoclonal Antibodies Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Therapeutic Monoclonal Antibodies Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Therapeutic Monoclonal Antibodies Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Therapeutic Monoclonal Antibodies Drug.

Chapter 14 and 15, to describe Therapeutic Monoclonal Antibodies Drug sales channel, distributors, customers, research findings and conclusion.